These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15988118)

  • 1. Prediction of theophylline clearance in CCl4-treated rats using in vivo CYP1A2 and CYP3A2 contents assessed with the PKCYP test.
    Kose N; Yamamoto K; Sai Y; Isawa M; Suwa T; Nakashima E
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):168-76. PubMed ID: 15988118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous assessment of the in vivo amount of CYP1A2 and CYP3A2 by the PKCYP-test using theophylline in rats.
    Matsunaga N; Hayashi M; Yamamoto K; Nishijima T; Kizu J; Nishihara K; Takanaka A; Morikawa A; Nakashima E
    Drug Metab Pharmacokinet; 2002; 17(3):190-8. PubMed ID: 15618669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of the PKCYP-test to predict the amount of in vivo CYP2C11 using tolbutamide as a probe.
    Matsunaga N; Nishijima T; Hattori K; Iizasa H; Yamamoto K; Kizu J; Takanaka A; Morikawa A; Nakashima E
    Biol Pharm Bull; 2001 Nov; 24(11):1305-10. PubMed ID: 11725969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the PKCYP-test in cases of altered CYP1A2 for multiple CYP systems in rat models of disease.
    Matsunaga N; Hattori K; Iizasa H; Kizu J; Takanaka A; Nakashima E
    Biol Pharm Bull; 2001 Sep; 24(9):1037-43. PubMed ID: 11558565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the PKCYP test to predict caffeine clearance mediated by CYP1A2 in a rat acute liver injury model.
    Matsunaga NK; Isawa M; Kizu J; Miyazaki N; Takanaka A; Nakashima E
    Drug Metab Pharmacokinet; 2003; 18(5):296-302. PubMed ID: 15619608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a newly developed ketolide antibiotic, telithromycin, on metabolism of theophylline and expression of cytochrome P450 in rats.
    Nosaka H; Nadai M; Kato M; Yasui K; Yoshizumi H; Miyoshi M; Zhao YL; Baba K; Takagi K; Hasegawa T
    Life Sci; 2006 May; 79(1):50-6. PubMed ID: 16423372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of midazolam pharmacokinetics in Wistar rats treated with lipopolysaccharide: relationship between total CYP and CYP3A2.
    Kato R; Yamashita S; Moriguchi J; Nakagawa M; Tsukura Y; Uchida K; Amano F; Hirotani Y; Ijiri Y; Tanaka K
    Innate Immun; 2008 Oct; 14(5):291-7. PubMed ID: 18809653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
    Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
    Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.
    Zhang X; Galinsky RE; Kimura RE; Quinney SK; Jones DR; Hall SD
    Drug Metab Dispos; 2010 Jan; 38(1):61-72. PubMed ID: 19797607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strain differences in hepatic cytochrome P450 1A and 3A expression between Sprague-Dawley and Wistar rats.
    Kishida T; Muto S; Hayashi M; Tsutsui M; Tanaka S; Murakami M; Kuroda J
    J Toxicol Sci; 2008 Oct; 33(4):447-57. PubMed ID: 18827444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Shenxiong Glucose Injection on the Activities of Six CYP Isozymes and Metabolism of Warfarin in Rats Assessed Using Probe Cocktail and Pharmacokinetic Approaches.
    Sun J; Lu Y; Li Y; Pan J; Liu C; Gong Z; Huang J; Zheng J; Zheng L; Li Y; Liu T; Wang Y
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29156621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats.
    Watanabe M; Tateishi T; Asoh M; Nakura H; Tanaka M; Kumai T; Kobayashi S
    Life Sci; 1998; 63(19):1685-92. PubMed ID: 9806224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.
    Britz H; Hanke N; Volz AK; Spigset O; Schwab M; Eissing T; Wendl T; Frechen S; Lehr T
    CPT Pharmacometrics Syst Pharmacol; 2019 May; 8(5):296-307. PubMed ID: 30762305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat.
    Eeckhoudt SL; Horsmans Y; Verbeeck RK
    Xenobiotica; 2002 Nov; 32(11):975-84. PubMed ID: 12487727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
    Reid JM; Kuffel MJ; Ruben SL; Morales JJ; Rinehart KL; Squillace DP; Ames MM
    Clin Cancer Res; 2002 Sep; 8(9):2952-62. PubMed ID: 12231541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats.
    Higashikawa F; Murakami T; Kaneda T; Takano M
    J Pharm Pharmacol; 1999 Apr; 51(4):405-10. PubMed ID: 10385212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum aminotransferase activity as a predictor of clearance of drugs metabolized by CYP isoforms in rats with acute hepatic failure induced by carbon tetrachloride.
    Yokogawa K; Watanabe M; Takeshita H; Nomura M; Mano Y; Miyamoto K
    Int J Pharm; 2004 Jan; 269(2):479-89. PubMed ID: 14706259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-related changes in hepatic expression and activity of cytochrome P450 in male rats.
    Yun KU; Oh SJ; Oh JM; Kang KW; Myung CS; Song GY; Kim BH; Kim SK
    Arch Toxicol; 2010 Dec; 84(12):939-46. PubMed ID: 20130842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.